Mild cognitive impairment: Symptomatic treatment

Amyvid.jpgAmyvid® scan showing amyloid deposition particularly heavy in frontal cortical gray matter. 

MIND “Memory Improvement Through Nicotine Dosing” ( NIA-funded through the Alzheimer’s Therapeutic Research Institute at USC. Uses titrated doses of nicotine patches vs. placebo patches. Age ≥55-90, MMSE≥23, CDR-0.5, abnormal memory scores on Logical Memory II Delayed Paragraph Recall subscale. Primary outcome measure is Conners Continuous Performance Task change from baseline over 24-month study. Secondary are MCI-Clinical Global Impression of Change and neurocognitive outcomes are performance on volumetric MRI, Cogstate Battery, CDR-SOB and ADCS-ADL-MCI scale and GDS.